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Introduction
Immune thrombocytopenic purpura (ITP) is a bleeding
disorder characterized by premature platelet destruction
mediated by autoantibodies. The incidence is around
100 cases in 1 million persons per year.1 Antiplatelet
agents, which are widely used in coronary artery disease
(CAD), are generally contraindicated in ITP patients.
We report an ITP patient with acute coronary syndrome
(ACS) who received percutaneous coronary interven-
tion (PCI) and discuss the strategy of treatment.
Case Report
A 71-year-old woman who had chronic refractory ITP
and hypertension was referred to our hospital for evalu-
ation because of ACS. Electrocardiography showed ST
segment depression in leads V3–6. Significant labora-
tory data included creatine kinase, 83U/L; troponin-I,
0.59ng/dL; platelets, 16,000/μL. Thallium-201 myo-
cardial perfusion scan showed ischemia in the anterior
and anterolateral area of the left ventricle. Because of
high risk of bleeding for invasive procedure, intravenous
dexamethasone 10 mg and immunoglobulin 27 g were
given daily for 5 days and the platelet count elevated to
119,000/μL. Aspirin 100 mg was administered before
PCI. Cardiac catheterization was performed through
the right radial artery using a 5 French, 16 cm long
sheath (Terumo Medical Corp, Somerset, NJ, USA).
Coronary angiography showed a 90% eccentric steno-
sis with plaque rupture in the midsegment of the left
anterior descending artery (Figure 1). The lesion was
predilated with a 3.5 ˜ 20 mm Crossail balloon
catheter (Guidant Corp, St Paul, MN, USA) and then
a 3.5 ˜ 18 mm Bx velocity stent (Cordis Corp, Miami
Lakes, FL, USA) was implanted and resulted in TIMI
grade 3 blood flow (Figure 2). The sheath was removed
immediately after the procedure. Clopidogrel 300 mg
was given immediately after stenting. Neither bleed-
ing nor ischemic events were noted during hospital-
ization. The patient continued to take aspirin 100 mg
for 2 days and clopidogrel 75 mg daily for 7 weeks.
Although occasional chest tightness was still noted,
multislice computed tomography of the heart showed
stent patency at 2 years’ follow-up.
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Discussion
ITP is an autoimmune disorder caused by autoantibod-
ies binding to platelet surface antigen and subsequently
accelerating platelet clearance by tissue macrophage.
Patients with a history of bleeding, being elderly and
refractory to treatment run the especially high risk 
of fatal bleeding. Therefore, medications to inhibit
platelet function are generally not recommended.
However, antiplatelet agents should be used in patients
with CAD unless contraindication exists, especially after
stent implantation. This dilemma leads to difficulty in
managing concomitant ITP and CAD.
Since our patient was categorized as having high
risk for major bleeding and had only a single coronary
lesion, PCI was a better choice than bypass surgery.
There are several concerns in a candidate with throm-
bocytopenia undergoing PCI. First, we have to mini-
mize the bleeding complication from the arterial
puncture site. Fuchi et al2 reported a 72-year-old
woman with ITP who underwent PCI and suffered
from hematoma around the femoral puncture site that
resulted in significant hypotension. We performed PCI
through radial access with a 5 French sheath trying to
lower the complication rate of entry site.3 Second,
immunoglobulin was used in our patient before cardiac
catheterization. The dosage we used was about 70% of
the recommended dosage in ITP patient undergoing
immediate intervention.1 A decision to choose a smaller
dose was based on previous reports of thromboembolic
complication in patients treated with immunoglobulin.
Third, low dose aspirin was given just before the proce-
dure and we monitored the patient with great caution
to avoid bleeding complication. During the pro-
cedure, we did not administer glycoprotein IIb/IIIa
inhibitor for fear of profound thrombocytopenia.
Although previous reports showed that glycoprotein
IIb/IIIa inhibitor could reduce the incidence of 
myocardial infarction, administration of glycoprotein
IIb/IIIa inhibitors may also further deteriorate platelet
function. Mendez et al4 recently reported a 70-year-old
man with ITP who underwent PCI and experienced
severe thrombocytopenia after abciximab adminis-
tration. In our case, the stent was implanted, followed
by aspirin 100 mg for 2 doses and clopidogrel 75 mg
daily for 7 weeks to prevent the risk of thrombosis in the
stented coronary artery. In the literature, we found 3
ITP cases who underwent stent implantation.2,5,6 Two
patients tolerated the antiplatelet treatment well for
several weeks without bleeding complication. One case
developed diffuse petechiae and nasal bleeding, which
recovered after clopidogrel was discontinued. In con-
clusion, patients with ITP and concomitant CAD are
not common, and definite treatment guidelines for
these patients have not been established. The case we
reported suggests that PCI is an available and safe
treatment for ITP patients with ACS. Hemostasis is the
major concern in managing these patients. Decision of
stent implantation (especially drug-eluting stent) is a
challenge; the risk and benefit of long-term antiplatelet
agent use should be considered in each patient and
should be individualized.
References
1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura.
N Engl J Med 2002;346:995–1008.
J Chin Med Assoc • September 2006 • Vol 69 • No 9 437
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Figure 1. Left coronary angiogram shows a critical stenosis (arrow)
in the midsegment of the left anterior descending artery.
Figure 2. Left anterior descending artery after stenting.
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